ARCH VENTURE FUND V, L.P.

Company

ALNYLAM PHARMACEUTICALS, INC.

Filed

June 10, 2004

Accession Number

0000950135-04-003045

A Schedule 13G is filed when a passive investor acquires more than 5% of a company's shares without intent to influence control. Learn more about SC 13G filings →